Vitamine D tegen prostaatkanker*
Uit een kleine Canadese studie blijkt het belang van goede bloedwaarden vitamine D bij prostaatkanker. In de studie kregen de 66 deelnemers, allen mannen met prostaatkanker die een operatie moesten ondergaan, dagelijks drie tot acht weken voorafgaande aan de operatie supplementen van vitamine D variërend in dosis van 10, 250 of 1.000 mcg. Vooral de hoge dosis zorgden voor hoge bloedwaarden vitamine D en voor hoge waarden van het actieve vitamine D hormoon calcitriol. Hoe hoger de bloedwaarden hoe lager de waarden van het antigen Ki67, een proteïne die de groei van de kankercellen weergeeft en hoe hoger de waarden van microRNA's die de groei van kankercellen tegengaan.
Oral Vitamin D Supplements Reduced Levels of Ki67 in Prostate Cancer Cells
Higher oral doses of plain vitamin D raised levels of calcitriol in prostate tissue. Higher prostate levels of calcitriol, a hormone made from vitamin D, corresponded with lower levels of the proliferation marker Ki67 and increased levels of cancer growth-inhibitory microRNAs in prostate cancer cells, according to data presented at the AACR Annual Meeting 2012.
The results not only point to the mechanisms by which vitamin D affects the rate of prostate cancer growth, but also indicate that vitamin D may slow the growth of prostate cancer cells -- a key finding given that the role of vitamin D in prostate cancer has been "controversial, with some suggesting that higher levels of vitamin D should be avoided," said Reinhold Vieth, Ph.D., professor at the University of Toronto in Toronto, Ontario, Canada.
"This study shows calcitriol makes the foot come off the gas pedal of cancer growth. We are not able to prove that the speed of the car has slowed down, but it certainly is a good sign," said Vieth. "We expect that this early-phase clinical trial will open the door for more detailed clinical research into the usefulness of vitamin D in the treatment or prevention of prostate cancer."
Vieth and colleagues previously reported that in men who were being monitored regularly for prostate cancer, higher vitamin D levels slowed the rate of rise in prostate-specific antigen levels. They randomly assigned 66 men scheduled for radical prostatectomy to daily vitamin D in doses of 400, 10,000 or 40,000 IU for three to eight weeks before surgery.
Researchers found that calcitriol levels in the prostate increased progressively with each daily dose of vitamin D, with 40,000 IU showing the highest levels. These higher levels of calcitriol corresponded with lower prostate levels of Ki67, a protein that indicates prostate cancer cell growth, as well as higher levels of specific growth-inhibitory microRNAs.
Vieth stressed that he and his colleagues do not advocate vitamin D supplementation in doses higher than 4,000 IU daily. Patients were assigned to the 40,000 IU daily dose because of the short presurgical time frame available for study, not as a regular regimen.
"Plain vitamin D provides the raw material to permit the body to take care of its own needs," he said. "We showed here that plain vitamin D allows the prostate to regulate its own level of calcitriol, and at the doses we used, for the time frame we used, it has been safe with the hoped-for desirable outcomes."
The next step in this line of research will be to conduct a phase III clinical trial in which men who are being monitored for prostate cancer progression will be randomly assigned to placebo or to a "high" dose of plain vitamin D.
This research was funded by the Canadian Cancer Society and was a collaboration between investigators at University Health Network, Sunnybrook Hospital and Mount Sinai Hospital, all in Toronto, and at the University of Chicago.
(Juni 2012)
Reacties: